|
GB201203051D0
(en)
*
|
2012-02-22 |
2012-04-04 |
Ucb Pharma Sa |
Biological products
|
|
KR101503341B1
(ko)
|
2014-03-12 |
2015-03-18 |
국립암센터 |
자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
|
|
KR20180016972A
(ko)
*
|
2015-02-22 |
2018-02-20 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Cd137에 결합하는 항체 치료제
|
|
CN114181309B
(zh)
*
|
2015-05-21 |
2024-07-30 |
鳄鱼生物科学公司 |
新型多肽
|
|
RU2769282C2
(ru)
|
2016-06-20 |
2022-03-30 |
Кимаб Лимитед |
Анти-PD-L1 и IL-2 цитокины
|
|
SG11201811184UA
(en)
|
2016-06-20 |
2019-01-30 |
F Star Beta Ltd |
Lag -3 binding members
|
|
WO2018011421A1
(en)
|
2016-07-14 |
2018-01-18 |
Genmab A/S |
Multispecific antibodies against cd40 and cd137
|
|
GB201612520D0
(en)
|
2016-07-19 |
2016-08-31 |
F-Star Beta Ltd |
Binding molecules
|
|
GB201619648D0
(en)
*
|
2016-11-21 |
2017-01-04 |
Alligator Bioscience Ab |
Novel antibodies and uses thereof
|
|
EP3544628A4
(en)
*
|
2016-11-23 |
2020-11-18 |
Immunoah Therapeutics, Inc. |
4-1BB BINDING PROTEINS AND THEIR USES
|
|
CN112210010B
(zh)
*
|
2017-01-06 |
2023-12-05 |
优特力克斯有限公司 |
抗-人4-1bb抗体及其应用
|
|
US20180325931A1
(en)
|
2017-01-21 |
2018-11-15 |
Ningbo Zhiming Biotechnology Co., Ltd. |
Use of paeoniflorin-6'-o-benzenesulfonate in treatment of sjögren's syndrome
|
|
AU2018224094B2
(en)
|
2017-02-24 |
2025-04-17 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
|
KR20240017409A
(ko)
*
|
2017-04-13 |
2024-02-07 |
아게누스 인코포레이티드 |
항-cd137 항체 및 이의 사용 방법
|
|
AU2018301393B2
(en)
|
2017-07-11 |
2025-02-27 |
Compass Therapeutics Llc |
Agonist antibodies that bind human CD137 and uses thereof
|
|
CA3071383C
(en)
*
|
2017-08-01 |
2022-04-12 |
Eli Lilly And Company |
Anti-cd137 antibodies
|
|
US11512134B2
(en)
|
2017-08-01 |
2022-11-29 |
Eli Lilly And Company |
Anti-CD137 antibodies
|
|
SG11202000198QA
(en)
|
2017-08-04 |
2020-02-27 |
Genmab As |
Binding agents binding to pd-l1 and cd137 and use thereof
|
|
WO2019036855A1
(en)
|
2017-08-21 |
2019-02-28 |
Adagene Inc. |
Anti-cd137 molecules and use thereof
|
|
US12202911B2
(en)
*
|
2017-10-10 |
2025-01-21 |
Numab Therapeutics AG |
Multispecific antibody comprising CD137 binding domain and PDL1 binding domain
|
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
|
TWI701259B
(zh)
*
|
2017-11-09 |
2020-08-11 |
大陸商上海懷越生物科技有限公司 |
４﹘１ｂｂ抗體及其製備方法和應用
|
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
|
WO2019104716A1
(en)
*
|
2017-12-01 |
2019-06-06 |
Adagene Inc. |
Methods for using cd137 ligand as biomarker for treatment with anti-cd137 antibody
|
|
EP3728316B1
(en)
|
2017-12-19 |
2025-02-26 |
invoX Pharma Limited |
Fc binding fragments comprising a pd-l1 antigen-binding site
|
|
WO2019148445A1
(en)
|
2018-02-02 |
2019-08-08 |
Adagene Inc. |
Precision/context-dependent activatable antibodies, and methods of making and using the same
|
|
CN111902429A
(zh)
*
|
2018-02-23 |
2020-11-06 |
拜斯科技术开发有限公司 |
多聚体双环肽配体
|
|
JP7059388B2
(ja)
|
2018-03-23 |
2022-04-25 |
イーライ リリー アンド カンパニー |
抗ｐｄ－ｌ１抗体との組み合わせのための抗ｃｄ１３７抗体
|
|
MX2020010653A
(es)
*
|
2018-04-09 |
2020-10-28 |
Origincell Therapeutics Co Ltd |
Anticuerpo anti-muerte programada-ligando 1 y su uso.
|
|
CA3099308A1
(en)
|
2018-05-21 |
2019-11-28 |
Compass Therapeutics Llc |
Compositions and methods for enhancing the killing of target cells by nk cells
|
|
BR112020026819A2
(pt)
*
|
2018-06-29 |
2021-04-20 |
Alector Llc |
anticorpos isolados, ácido nucleico, vetor, células hospedeiras, método de produção de um anticorpo, composição farmacêutica, métodos para tratar o câncer e para tratar uma doença e usos de um anticorpo
|
|
PT3820569T
(pt)
|
2018-07-12 |
2025-01-14 |
Invox Pharma Ltd |
Moléculas de anticorpo que se ligam a pd-l1 e cd137
|
|
GB201811408D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
CD137 Binding Molecules
|
|
GB201811410D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
OX40 Binding molecules
|
|
GB201811415D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-Mesothelin Anti bodies
|
|
ES3044118T3
(en)
|
2018-07-12 |
2025-11-26 |
Invox Pharma Ltd |
Antibody molecules that bind cd137 and ox40
|
|
GB201811450D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Delta Ltd |
Mesothelin and CD137 binding molecules
|
|
GB201811404D0
(en)
*
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Anti-CD137 Antibodies
|
|
GB201811403D0
(en)
|
2018-07-12 |
2018-08-29 |
F Star Beta Ltd |
Antibody molecules
|
|
JP7090204B2
(ja)
*
|
2018-07-19 |
2022-06-23 |
イーライ リリー アンド カンパニー |
免疫チェックポイントを標的とする二重特異性抗体
|
|
CN112739339B
(zh)
|
2018-07-23 |
2024-12-27 |
海德堡医药研究有限责任公司 |
抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
|
|
EP3827019A1
(en)
|
2018-07-24 |
2021-06-02 |
Inhibrx, Inc. |
Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same
|
|
SG11202102335YA
(en)
|
2018-09-12 |
2021-04-29 |
Eucure Beijing Biopharma Co Ltd |
Anti-tnfrsf9 antibodies and uses thereof
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
CN120623346A
(zh)
|
2018-10-11 |
2025-09-12 |
因荷布瑞克斯生物科学公司 |
Pd-1单结构域抗体及其治疗组合物
|
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Ｄｌｌ３シングルドメイン抗体およびその治療用組成物
|
|
JP2022504802A
(ja)
|
2018-10-11 |
2022-01-13 |
インヒブルクス インコーポレイテッド |
５ｔ４シングルドメイン抗体およびその治療組成物
|
|
CN113286825B
(zh)
*
|
2018-11-30 |
2024-06-18 |
爱必乐生物公司 |
抗pd-l1/抗4-1bb双特异性抗体及其用途
|
|
CN120098128A
(zh)
*
|
2019-01-02 |
2025-06-06 |
Qlsf生物治疗药物公司 |
Cd137激动剂抗体及其用途
|
|
WO2020180398A1
(en)
*
|
2019-01-14 |
2020-09-10 |
The Regents Of The University Of California |
Compositions and methods for modulating cellular internalization
|
|
KR20210133261A
(ko)
*
|
2019-02-26 |
2021-11-05 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Bcma에 결합하는 항원 결합 단백질
|
|
NZ781538A
(en)
|
2019-04-24 |
2025-12-19 |
Heidelberg Pharma Res Gmbh |
Amatoxin antibody-drug conjugates and uses thereof
|
|
WO2020247290A1
(en)
*
|
2019-06-04 |
2020-12-10 |
Academia Sinica |
Ligands targed to epidermal growth factor receptors and compositions for use in treating tumors
|
|
CN120441704A
(zh)
|
2019-06-26 |
2025-08-08 |
圆祥生技股份有限公司 |
T细胞活化抗体
|
|
JP7634001B2
(ja)
*
|
2019-10-11 |
2025-02-20 |
ナンチン リーズ バイオラブス カンパニー，リミティド |
４－１ｂｂに結合する抗体およびその用途
|
|
EP4100439A4
(en)
*
|
2020-02-05 |
2024-05-29 |
The Board Of Regents Of The University Of Texas System |
NOVEL LILRB2 ANTIBODIES AND USES THEREOF
|
|
CN115605228A
(zh)
*
|
2020-04-17 |
2023-01-13 |
苏州丁孚靶点生物技术有限公司（Cn） |
一种特异性结合cd137的制剂及其用途
|
|
WO2021236658A1
(en)
|
2020-05-19 |
2021-11-25 |
Boehringer Ingelheim International Gmbh |
Binding molecules for the treatment of cancer
|
|
CN113842456B
(zh)
*
|
2020-06-28 |
2022-07-26 |
上海齐鲁制药研究中心有限公司 |
一种抗人4-1bb的单克隆抗体制剂及其用途
|
|
CN116194124A
(zh)
*
|
2020-07-31 |
2023-05-30 |
中外制药株式会社 |
包含表达嵌合受体的细胞的药物组合物
|
|
WO2023098785A1
(zh)
*
|
2021-12-01 |
2023-06-08 |
上海君实生物医药科技股份有限公司 |
抗4-1bb抗体及其用途
|
|
CN115975032B
(zh)
*
|
2022-12-19 |
2024-06-07 |
华润生物医药有限公司 |
一种cldn18.2抗体及其应用
|
|
AU2024330458A1
(en)
*
|
2023-09-01 |
2026-02-12 |
Amgen Inc. |
Molecules for treatment of cancer
|
|
WO2025189194A1
(en)
*
|
2024-03-08 |
2025-09-12 |
Dana-Farber Cancer Institute, Inc. |
Antibodies against vegf and methods of use thereof
|